Company Overview
- Headquarters
- 4340 Duncan Ave. Suite 210 St. Louis, MO 63110
- Website
- accuronix.com
- Employees
- 1
- Industry
- Scientific Research
- SIC Code
-
8732 - Commercial Economic, Sociological, and Educational Research
- Company Culture
-
develop novel oncology therapiesinitial focus in pancreatic cancer
Financials & Stats
Revenue
$3B
Competitive Advantages
Who is Accuronix Therapeutics Inc
Accuronix is a company focused on developing novel cancer therapies. The company's primary field of activity is within the healthcare industry. Accuronix is located at 4340 Duncan Ave. Suite 210 St. Louis, MO 63110. The company's President and CEO is Bradley T. Keller, Ph.D. Accuronix operates with an initial focus on pancreatic cancer. The company utilizes a novel drug-targeting technology. This technology selectively targets σ-2 receptors, which are overexpressed on cancer cells. Accuronix aims to develop novel oncology therapies. The company's competitive advantages include its novel drug-targeting technology and its ability to selectively target σ-2 receptors overexpressed on cancer cells. Accuronix's mission is to develop novel oncology therapies, with an initial focus on pancreatic cancer. The company's email contact is [email protected].
Company Leadership
Accuronix Therapeutics Inc Industry Tags
Accuronix Therapeutics Inc Tech Stack
Companies Similar to Accuronix Therapeutics Inc
Analyze industry trends and opportunities by examining competitors and companies comparable to Accuronix Therapeutics Inc, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 3M | 9 | Rochester, NY | 2009 | |
| 3M | 7 | Phoenix, AZ | 2020 | |
| 3M | 5 | Chicago, IL | 2009 | |
| 3M | 9 | Schaumburg, IL | ||
| 3M | 12 | New York, NY | 2017 |